Source: International Congress 2019 – Interstitial lung disease registries
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Vasakova (Prague, Czech Republic), M. Sterclova (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), K. Lawandowska (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Hajkova (Bratislava, Slovakia), D. Jovanovic (Belgrade, Republic of Serbia), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Kramer (Petah Tikva, Israel), M. Studnicka (Salzburg, Austria), N. Stoeva (Sofia, Bulgaria), S. Littnerova (Brno, Czech Republic), K. Hejduk (Brno, Czech Republic), L. Dusek (Brno, Czech Republic). Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidone or nintedanib or their switch. Real world data from the EMPIRE registry.. 4720

Member's Comments

No comment yet.

Related content which might interest you: Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis?  Real- world results from the EMPIRE registry. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients? Source: Eur Respir Rev 2011; 20: 201-207 Year: 2011 Mortality outcomes in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a real world study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019 Year: 2020 Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Clinical and biological predictors of progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated by erlotinib in the ERMETIC cohort Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010 Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study Source: Eur Respir J 2012; 40: 101-109 Year: 2012 The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Interim data from the RECAP extension study Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2011 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): final data from INPULSIS-ON Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 The effect of treatment with pirfenidone on death or lung transplantation in patients with idiopathic pulmonary fibrosis (IPF): Analysis of outcomes in the CAPACITY (CAP) trials Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry Source: ERJ Open Res, 5 (3) 00170-2018; 10.1183/23120541.00170-2018 Year: 2019 The importance of the disease-free survival (DFS) endpoint to survivors of lung cancer Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021 Oral anticoagulation therapy in pediatric pulmonary hypertension: A 10-year registry survival analysis Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects Year: 2010 Long-term prognosis in rehabilitated COPD patients. A 3-year controlled study and a 3-year follow-up Source: Eur Respir J 2001; 18: Suppl. 33, 224s Year: 2001 Impact on recurrence and long-term survival Source: Annual Congress 2004 - Impact of neoadjuvant treatments on morbidity and oncological outcome of patients with NSCLC Year: 2004 Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017